Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 3108-3114, May 1, 2008. doi: 10.1158/0008-5472.CAN-07-5644
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Smid, M.
Right arrow Articles by Martens, J. W.M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smid, M.
Right arrow Articles by Martens, J. W.M.

Molecular Biology, Pathobiology, and Genetics

Subtypes of Breast Cancer Show Preferential Site of Relapse

Marcel Smid1,2, Yixin Wang3, Yi Zhang3, Anieta M. Sieuwerts1, Jack Yu3, Jan G.M. Klijn1, John A. Foekens1 and John W.M. Martens1

1 Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute; 2 Cancer Genomics Centre, Rotterdam, the Netherlands; and 3 Veridex LLC, a Johnson & Johnson Company, San Diego, California

Requests for reprints: John W.M. Martens, Erasmus MC, Josephine Nefkens Institute, Department of Medical Oncology, Room Be400 P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. Phone: 31-0-10-4088372; Fax: 31-0-10-4088377; E-mail: j.martens{at}erasmusmc.nl.

Key Words: breast cancer • molecular subtypes • site of relapse • metastasis • pathway analysis

We explored whether the five previously reported molecular subtypes in breast cancer show a preference for organ-specific relapse and searched for molecular pathways involved. The "intrinsic" gene list describing the subtypes was used to classify 344 primary breast tumors of lymph node–negative patients. Fisher exact tests were used to determine the association between a tumor subtype and a particular site of distant relapse in these patients who only received local treatment. Modulated genes and pathways were identified in the various groups using Significance Analysis of Microarrays and Global Testing. Bone relapse patients were most abundant in the luminal subtypes but were found less than expected in the basal subtype. The reverse was true for lung and brain relapse patients with the remark that absence of lung relapse was luminal A specific. Finally, a pleura relapse, although rare, was found almost exclusively in both luminal subtypes. Many differentially expressed genes were identified, of which several were in common in a subtype and the site to which the subtype preferentially relapsed. WNT signaling was up-regulated in the basal subtype and in brain-specific relapse, and down-modulated in the luminal B subtype and in bone-specific relapse. Focal adhesion was found up-regulated in the luminal A subtype but down-regulated in lung relapse. The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site. [Cancer Res 2008;68(9):3108–14]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.